Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Drug Class
3.3. Snippet by Route of Administration
3.4. Snippet by End User
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rise in the Prevalence of Polycythemia
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. Complications Associated with the Drugs
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. By Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
6.1.2. Market Attractiveness Index, By Type
6.2. Primary polycythemia*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Secondary polycythemia
6.4. Pseudopolycythemia
7. By Drug Class
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
7.1.2. Market Attractiveness Index, By Drug Class
7.2. Antimetabolites*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.2.3. Hydroxyurea
7.2.4. Methotrexate
7.2.5. Cytarabine
7.3. JAK2 inhibitors
7.4. Myelosuppressive Agents
7.5. Selective Serotonin Reuptake Inhibitors
7.6. Folic acid
7.7. Others
8. By Route of Administration
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.1.2. Market Attractiveness Index, By Route of Administration
8.2. Oral*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Intravenous
8.4. Intramuscular
9. By Distribution Channel
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Hospital Pharmacies*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Retail Pharmacies
9.4. Online Pharmacies
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.7.1. U.S.
10.2.7.2. Canada
10.2.7.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.7.1. Germany
10.3.7.2. U.K.
10.3.7.3. France
10.3.7.4. Spain
10.3.7.5. Italy
10.3.7.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.7.1. Brazil
10.4.7.2. Argentina
10.4.7.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.7.1. China
10.5.7.2. India
10.5.7.3. Japan
10.5.7.4. South Korea
10.5.7.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
Key Market Players
12.1. Novartis AG*
12.1.1. Company Overview
12.1.2. Product Portfolio
12.1.2.1. Product Description
12.1.2.2. Product Key Performance Indicators (KPIs)
12.1.2.3. Historic and Forecasted Product Sales
12.1.2.4. Product Sales Volume
12.1.3. Financial Overview
12.1.3.1. Company Revenue’s
12.1.3.2. Geographical Revenue Shares
12.1.3.3. Revenue Forecasts
12.1.4. Key Developments
12.1.4.1. Mergers & Acquisitions
12.1.4.2. Key Product Development Activities
12.1.4.3. Regulatory Approvals etc.
12.1.5. SWOT Analysis
12.2. Incyte Corporation
12.3. Bristol-Myers Squibb Company
12.4. PharmaEssentia Corporation
12.5. TAJ LIFE SCIENCES PVT. LTD
12.6. Genetec Lifesciences
12.7. Teva Pharmaceuticals
12.8. Medyra Pharmaceuticals
12.9. Viatris
12.10. Apotex Inc
* Similar data will be provided for each market player.
Emerging Market Players
12.11. DiscMedicine*
12.11.1. Pipeline Products Description
12.11.2. Product Key Performance Indicators (KPIs)
12.11.3. Key Activities
12.11.4. Market Entry Timelines
12.11.5. Product Penetration Rate
12.11.6. Sales Estimation and Projections
12.12. Silence Therapeutics
12.13. Takeda Pharmaceuticals
* Similar data will be provided for each market player.
LIST NOT EXHAUSTIVE
12. Appendix
12.1 About Us and Services
12.2 Contact Us